FDA approves Xience Prime Everolimus Coronary Stent

The FDA has given approval for the next-generation Xience Prime Everolimus Eluting Coronary Stent System (Xience Prime),from Abbott Vascular, for the treatment of coronary artery disease. The decision was supported by the clinical results from the SPIRIT group of trials. Xience Prime uses the same drug and biocompatible polymer as the Xience V Everolimus Eluting Coronary Stent System and features an enhanced stent design and a delivery system designed for greater flexibility, ideal radial strength, excellent longitudinal strength and more accurate stent placement.For the first time physicians have a 38 mm everolimus-eluting stent for the treatment of long lesions. Xience Prime already has CE Mark approval in Europe.